Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$10.0B
75M shares
52-week range
$34.34 – $133.16
100% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.26%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $1.4M |
| Gross profit | $0 | $0 | $0 | −$1.4M |
| Gross margin | — | — | — | — |
| R&D | $27.8M | $68.4M | $167.9M | $214.7M |
| Operating income | −$30.7M | −$93.0M | −$216.9M | −$285.6M |
| EBITDA | −$39.8M | −$75.0M | −$181.9M | −$254.1M |
| Net income | −$39.8M | −$84.0M | −$182.1M | −$255.8M |
| Net margin | — | — | — | — |
| EPS (diluted) | -0.79 | -1.66 | -3.30 | -4.22 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $9M | $-4.44 | $-4.78–$-4.24 | 10 |
| 2027 | $12M | $-5.54 | $-6.30–$-4.94 | 10 |
| 2028 | $54M | $-6.08 | $-12.69–$-2.72 | 11 |
| 2029 | $239M | $-5.57 | $-5.57–$-5.57 | 4 |
Forward consensus · source: Financial Modeling Prep
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
www.apogeetherapeutics.comNo one on the platform currently holds APGE.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-06-30 | 41,100 | $1.8M |
| Execution date | Ratio |
|---|---|
| 2008-01-08 | 1-for-50reverse |
No one on the platform has traded APGE yet.
| $6.3B |
| — |
| IRONDisc Medicine, Inc. | $74.76 | -0.03% | $2.9B | — |
| LEGNLegend Biotech Corporation | $29.13 | +1.53% | $5.4B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
@TrendEdgeLogan AbbVie's $11 Billion Immunology Bet. $APGE rocketed to 132USD
View on StockTwits ↗$EVMN tic toc 👀 Loaded shares today. Especially with $APGE buyout, positive results will really skyrocket
View on StockTwits ↗Healthcare stocks attracted strong investor demand this week as money rotated out of technology shares, pushing AbbVie, Eli Lilly and Johnson & Johnson to record closing highs. The sector benefited from its defensive characteristics and confidence in the long-term growth prospects of leading pharmaceutical companies. AbbVie's shares received an additional boost after the company announced plans to acquire Apogee Therapeutics, strengthening its drug development pipeline. According to RBC Capital Markets, AbbVie, Eli Lilly and Johnson & Johnson have largely avoided the operational setbacks that forced several competitors to restructure, while making strategic acquisitions that enhance future growth opportunities. Other biopharmaceutical companies, including Regeneron, Sanofi, Moderna and Absci, also advanced, lifting healthcare-focused ETFs as investors sought stability amid weakness in technology stocks and growing uncertainty around AI-related valuations. $ABBV $APGE $REGN $SNY $LLY
View on StockTwits ↗$SLS $APGE Biotech M&A season is HERE. The Apogee Therapeutics deal turned the volume all the way up. Big pharma is officially back in buy mode. Wall Street is actively hunting. Analysts have their eyes on the next wave of takeover targets. Apogee Therapeutics changed the game. AbbVie paid $10.9B for a pre-commercial immunology biotech. Big pharma shows that level of conviction. Investors immediately start scanning for the next company with: - Strong Phase 2/3 data - Clean balance sheets - Undervalued market caps - Assets in immunology, inflammation, or rare disease - Strategic fit for pharma facing patent cliffs. SLS Next up. 🙏✌️❤️🩹
View on StockTwits ↗$APGE This stock is the luckiest on the street..Had the deal happened just a couple of days ago later that it did, it would have been sub 100 for sure!! Can’t they renegotiate this deal?
View on StockTwits ↗RECAP 6/24 +Pos Comments: $PAC + Itau BBA $MHO + Freedom Broker RECAP 6/24 -Neg Comments: $APGE - Stifel $MCHP - J capital
View on StockTwits ↗RECAP 6/24 +Pos Comments: $PAC + Itau BBA $MHO + Freedom Broker RECAP 6/24 -Neg Comments: $APGE - Stifel $MCHP - J capital Live Breaking trading news www.openoutcrier.com
View on StockTwits ↗$APGE https://anachart.com/wp-content/uploads/2026/06/1782295269_soc-img.jpg
View on StockTwits ↗$APGE this one just might get a secondary unsolicited buyout offer from another big player 🤑
View on StockTwits ↗Canaccord⬆️ $ABBV-$273, reit Buy/said: ABBV's acquisition of $APGE for ~$10.1B net makes very good strategic sense adding a potential mega-blockbuster Immunology asset for AD/asthma that should be a major growth driver in the next decade. KYMR CRVS ORKA REGN - SNY $LLY Here's what else Canaccord Genuity had to say: https://x.com/Quantumup1/status/2069410413242921075?s=20
View on StockTwits ↗H.C. Wainwright reiterated $ORKA Buy-$120 UCBJY JNJ - PTGX ALMS TAK H.C. Wainwright commented on y'day's $APGE and $ABBV M&A deal, pointing to Apogee's similarity to Oruka, as it was incepted by privately-held Paragon Therapeutics, and additionally said: In our view, Oruka and Apogee have many points of commonality, including a focus on I&I (particularly inflammatory skin diseases) and the intent to advance investigational agents with best-in-disease potential. We reiterate our Buy rating and 12-month price target of $120 per share.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.